Loading…
Loading…
GLABF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for GLABF and 80,000+ other tickers.
See exactly how GLABF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for GLABF and 80,000+ other tickers.
Gemina Laboratories Ltd. is a Canadian biotechnology enterprise primarily focused on the investigation, creation, and commercialization of in vitro diagnostic solutions. The firm's innovation extends to developing unique surface functionalization chemistries specifically designed for the identification of pathogens and various biological markers. A significant ongoing project is the POC Antigen COVID test, a rapid, point-of-care lateral flow assay strip intended to determine active COVID-19 infections. The company maintains its corporate headquarters in Vancouver, Canada.
VANCOUVER, BC / ACCESS Newswire / March 25, 2026 / Gemina Laboratories Ltd. (CSE:GLAB) ("Gemina" or the "Company") announces that that the Canadian Securities Exchange (the "CSE") has approved is application to voluntarily delist its common shares from trading on the CSE.
VANCOUVER, BC / ACCESS Newswire / October 1, 2025 / Gemina Laboratories Ltd. (CSE:GLAB) (the "Company" or "Gemina") announces that further to its news release dated November 13, 2024, the Company will not be proceeding with the non-brokered private placement of up to $7,000,000 at a price of $0.75 per common share.
VANCOUVER, BC / ACCESSWIRE / November 13, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7)(OCTQB:GLABF) (the "Company" or "Gemina") is pleased to announce a non-brokered private placement offering (the "Offering") of up to 9,333,333 common shares in the capital of the Company (each, a "Share") at a price of $0.75 per Share.
ACCELERATING COMMERCIALISATION VANCOUVER, BC / ACCESSWIRE / July 10, 2024 / Gemina Laboratories Ltd (CSE:GLAB)(OTCQB:GLABF)(FRA:8I7) (the "Company" or "Gemina") is pleased to provide a strategic update and summary of progress in H1 2024. In our last strategic update in March the Company indicated a focus on developing multiple revenue streams, including product development, licenses, and services.